Points to consider for ethics committees in human gene therapy trials

Bioethics

Volumn 15, Issue 5-6, 2001, Pages 491-500

  Dettweiler, Ulrich ^a,b   Simon, Perikles ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

CLINICAL RESEARCH; CONFERENCE PAPER; DEATH; GENE THERAPY; HEALTH CARE POLICY; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; PATIENT CARE; POLITICS; RISK ASSESSMENT; SAFETY; UNITED STATES;

EID: 0034757732     PISSN: 02699702     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-8519.00257     Document Type: Conference Paper

References (14)

1. Principles of human gene therapy studies
2. Gene therapy on trial
3. A phase I study of adenoviral vector mediated gene transfer to liver in adults with partial ornithine transcarbamylase deficiency protocol, ORDA consolidated review
4. Tighter watch urged on adenoviral vectors
5. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors
6. bc1-2 gene therapy exacerbates excitotoxicity
7. Cross-species comparison of in vivo reporter gene expression after recombinant adeno-associated virus-mediated retinal transduction
8. Trust and distrust in professional ethics
9. Declaration of Helsinki: Ethical principals for medical research involving human subjects